Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 9:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: SUBOXONE Clear all
Completed Phase 1 Interventional Results available

Drug Interaction Study With BI 201335 and Methadone or Buprenorphine/Naloxone

NCT01637922
View directory record Official record
Conditions
Hepatitis C
Interventions
BI 201335
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 64 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
3
States / cities
Atlanta, Georgia • Overland Park, Kansas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 2, 2015 · Synced Sep 26, 2026, 9:41 PM EDT
Recruiting Phase 2Phase 3 Interventional

Efficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder

NCT05011266
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Buprenorphine/naloxone, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Rockville, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 26, 2026, 9:41 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone

NCT07314346
View directory record Official record
Conditions
Healthy Volunteer Study
Interventions
Buprenorphine/Naloxone + BEM/RZR, Methadone +BEM/RZR
Drug
Lead sponsor
Atea Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Hollywood, Florida • Overland Park, Kansas • Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 26, 2026, 9:41 PM EDT
Not listed No phase listed Observational

Evaluating the Pharmacokinetics and Patient Outcomes of Buprenorphine Microdosing

NCT05307458
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Withdrawal
Interventions
Buprenorphine/naloxone
Drug
Lead sponsor
United Health Services Hospitals, Inc.
Other
Eligibility
18 Years and older
Enrollment
20 participants
Timeline
2022 – 2024
U.S. locations
1
States / cities
Binghamton, New York
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Sep 26, 2026, 9:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Interaction of Buprenorphine With HIV Medications and Tuberculosis Medications

NCT00877591
View directory record Official record
Conditions
Opioid Dependency, HIV Infections
Interventions
Fosamprenavir/Ritonavir, Darunavir/Ritonavir, Rifampin, Rifabutin, Buprenorphine
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 5, 2014 · Synced Sep 26, 2026, 9:41 PM EDT
Terminated Not applicable Interventional Results available

Reward-based Technology to Improve OUD Treatment

NCT05180669
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
OARSCM Software Application, MyMAT Software Application
Other
Lead sponsor
Q2i, LLC
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Sep 26, 2026, 9:41 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

XRB vs. SLB in Jail and at Re-entry: Pilot, Proof of Concept

NCT03604159
View directory record Official record
Conditions
Opioid Dependence
Interventions
Buprenorphine Extended Release, Sublingual Buprenorphine (SUBOXONE, Zubsolv, or generic tablets)
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 60 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Sep 26, 2026, 9:41 PM EDT
Active, not recruiting Not applicable Interventional

Counseling for Harm Reduction and Retention in Medication-assisted Treatment - Cherokee Nation

NCT05733442
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Treatment as usual (TAU), CHaRRM-CN
Other
Lead sponsor
Washington State University
Other
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Tahlequah, Oklahoma • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 26, 2026, 9:41 PM EDT
Completed Phase 2 Interventional Results available

Veterans' Pain Care Organizational Improvement Comparative Effectiveness Study

NCT03026790
View directory record Official record
Conditions
Chronic Pain
Interventions
Medication management, Non-pharmacological pain management, Buprenorphine-Naloxone
Other · Drug
Lead sponsor
University of Minnesota
Other
Eligibility
21 Years and older
Enrollment
820 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 4, 2023 · Synced Sep 26, 2026, 9:41 PM EDT
Not listed Phase 1Phase 2 Interventional

Sublingual Buprenorphine Treatment for Neonatal Abstinence Syndrome - Pilot Study

NCT02249026
View directory record Official record
Conditions
Drug; Withdrawal Symptoms, Neonatal, Withdrawal, Fetus and Newborn Affected by Other Maternal Medication
Interventions
BZDs + opiate exposure treated with BPN, Opiates exposure treated with BPN
Drug
Lead sponsor
Gauda, Estelle B., M.D.
Individual
Eligibility
Up to 7 Days
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated May 5, 2016 · Synced Sep 26, 2026, 9:41 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Effects of Water Temperature on the Cold Pressor Test

NCT03083626
View directory record Official record
Conditions
Chronic Pain
Interventions
Cold pressor test
Other
Lead sponsor
Georgetown University
Other
Eligibility
21 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Sep 26, 2026, 9:41 PM EDT
Completed Phase 1Phase 2 Interventional

Buprenorphine Formulation Comparison: Sublingual Tablet vs. Solution - 1

NCT00000320
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine formulation: liquid vs. tablet
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 1999
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 26, 2026, 9:41 PM EDT
Completed Phase 4 Interventional Results available

Buprenorphine and Methadone for Opioid-dependent Chronic Back Pain Patients

NCT01559454
View directory record Official record
Conditions
Low Back Pain
Interventions
Methadone, Buprenorphine/naloxone
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Amherst, New York
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Sep 26, 2026, 9:41 PM EDT
Completed Phase 1 Interventional

Drug-Drug Interaction Study Between Telaprevir and Buprenorphine

NCT01275599
View directory record Official record
Conditions
Hepatitis C, Opioid-Related Disorders
Interventions
telaprevir, buprenorphine/naloxone
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 64 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
2
States / cities
Overland Park, Kansas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 7, 2011 · Synced Sep 26, 2026, 9:41 PM EDT
Terminated Phase 4 Interventional

Novel Induction to Buprenorphine/Naloxone

NCT05644587
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Use, Opioid Abuse, Opioid Misuse, Opioid Dependence
Interventions
buprenorphine/naloxone
Drug
Lead sponsor
Bicycle Health
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Sep 26, 2026, 9:41 PM EDT
Completed Phase 2 Interventional

Buprenorphine Combination Tablet Feasibility - 1

NCT00000298
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine/naloxone
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 16, 2005 · Synced Sep 26, 2026, 9:41 PM EDT
Completed Phase 1 Interventional

Study of the Treatment of Experimental Pain in Opioid Dependent Persons on Methadone or Buprenorphine Maintenance

NCT01642030
View directory record Official record
Conditions
Opioid Dependence, Pain, Addiction
Interventions
Placebo, Hydromorphone, Buprenorphine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 55 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 10, 2017 · Synced Sep 26, 2026, 9:41 PM EDT
Recruiting Early Phase 1 Interventional

A Clinical Trial Comparing Buprenorphine Formulations for High Potency Synthetic Opioid Use

NCT06726200
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Buprenorphine + naloxone (Suboxone), Buprenorphine Injection
Drug
Lead sponsor
Rachel R. Luba
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 26, 2026, 9:41 PM EDT
Withdrawn Phase 2 Interventional

Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-2 - 5

NCT00000330
View directory record Official record
Conditions
Heroin Dependence, Opioid-Related Disorders
Interventions
Opioid-Related Disorders
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 3, 2017 · Synced Sep 26, 2026, 9:41 PM EDT
Completed Phase 3 Interventional

Extended-release Buprenorphine Compared to Sublingual Buprenorphine in Rural Settings (RXR)

NCT06023459
View directory record Official record
Conditions
Opioid-Related Disorders, Substance-Related Disorders, Narcotic-Related Disorders
Interventions
Injectable extended-release buprenorphine, Sublingual buprenorphine-naloxone
Drug
Lead sponsor
Yih-Ing Hser
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
7
States / cities
El Dorado, Arkansas • Garberville, California • Gibson City, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 26, 2026, 9:41 PM EDT
Completed Phase 3 Interventional Results available

Neuroimaging Predictors of Relapse During Treatment for Opiate Dependence

NCT02696096
View directory record Official record
Conditions
Opioid Addiction
Interventions
FMRI, Suboxone
Other · Drug
Lead sponsor
Butler Hospital
Other
Eligibility
21 Years to 50 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 16, 2022 · Synced Sep 26, 2026, 9:41 PM EDT
Completed Phase 3 Interventional Results available

Clinical Trial of CAM2038, Long-acting Subcutaneous Buprenorphine Injections for Treatment of Patients With Opioid Dependence

NCT02651584
View directory record Official record
Conditions
Opioid Use Disorders
Interventions
CAM2038 SC injection, SL BPN/NX tabs, placebo SC injections, SL placebo tablets
Drug
Lead sponsor
Braeburn Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
36
States / cities
Birmingham, Alabama • Haleyville, Alabama • Hamilton, Alabama + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Sep 26, 2026, 9:41 PM EDT
Suspended Phase 3 Interventional Accepts healthy volunteers

Buprenorphine for Probationers and Parolees: Bridging the Gap Into Treatment

NCT03616236
View directory record Official record
Conditions
Opioid Use
Interventions
Buprenorphine/Naloxone, Treatment as usual
Drug · Other
Lead sponsor
Friends Research Institute, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Sep 26, 2026, 9:41 PM EDT
Completed No phase listed Observational

Effect of Heroin Use on Immune Activation and Cardiovascular Risk in HIV

NCT03976258
View directory record Official record
Conditions
HIV Infection, Opioid-use Disorder, Cardiovascular Diseases
Interventions
buprenorphine/naloxone, Methadone, Naltrexone Injection, Heroin
Drug
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 1, 2023 · Synced Sep 26, 2026, 9:41 PM EDT